Very long chain omega-3 (n-3) fatty acids and human health

European Journal of Lipid Science and Technology

Volumn 116, Issue 10, 2014, Pages 1280-1300

  Calder, Philip C ^a,b,c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Brain; Cancer; Cardiovascular disease; Development; Diet; Docosahexaenoic acid; Eicosanoids; Eicosapentaenoic acid; Fish oil; Inflammation

Indexed keywords

EID: 84907960261     PISSN: 14387697     EISSN: 14389312     Source Type: Journal    
DOI: 10.1002/ejlt.201400025     Document Type: Article

References (230)

1. Calder, P. C., Yaqoob, P., Understanding omega-3 polyunsaturated fatty acids. Postgrad. Med. 2009, 121, 148-157.
2. Kaur, G., Cameron-Smith, D., Garg, M., Sinclair, A. J., Docosapentaenoic acid (22:5n-3): A review of its biological effects. Prog. Lipid Res. 2011, 50, 28-34.
3. Blasbalg, T. L., Hibbeln, J. R., Ramsden, C. E., Majchrzak, S. F., Rawlings, R. R., Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. Am. J. Clin. Nutr. 2011, 93, 950-962.
4. Burdge, G. C., Calder, P. C., Dietary α-linolenic acid and health-related outcomes: A metabolic perspective. Nutr. Res. Rev. 2006, 19, 26-52.
5. Vessby, B., Gustafsson, I. B., Tengblad, S., Boberg, M., Andersson, A., Desaturation and elongation of fatty acids and insulin action. Ann. N.Y. Acad. Sci. 2002, 967, 183-195.
6. Childs, C. E., Romeu-Nadal, M., Burdge, G. C., Calder, P. C., Gender differences in the n-3 fatty acid content of tissues. Proc. Nutr. Soc. 2008, 67, 19-27.
7. Koletzko, B., Lattka, E., Zeilinger, S., Illig, T., Steer, C., Genetic variants of th fatty acid desaturase gene cluster predict amounts of red blood cell docosahexaenoic acid and other polyunsaturated fatty acids in pregnant women: Findings from the Avon Longitudinal Study of Parents and Children. Am. J. Clin. Nutr. 2011, 93, 211-219.
8. Bolton-Smith, C., Woodward, M., Tavendale, R., Evidence for age-related differences in the fatty acid composition of human adipose tissue, independent of diet. Eur. J. Clin. Nutr. 1997, 51, 619-624.
9. Conquer, J. A., Holub, B. J., Dietary docosahexaenoic acid as a source of eicosapentaenoic acid in vegetarians and omnivores. Lipids 1997, 32, 341-345.
10. British Nutrition Foundation: N-3 Fatty Acids and Health. British Nutrition Foundation, London (United Kingdom) 1999.
11. Scientific Advisory Committee on Nutrition/Committee on Toxicity: Advice on Fish Consumption: Benefits and Risks. TSO, London (United Kingdom) 2004.
12. Aidos, I., van der Padt, A., Luten, J. B., Boom, R. M., Seasonal changes in crude and lipid composition of herring fillets, byproducts, and respective oils. J. Agric. Food Chem. 2002, 50, 4589-4599.
13. Cordier, M., Brichon, G., Weber, J. M., Zwingelstein, G., Changes in the fatty acid composition of phospholipids in tissues of farmed sea bass (Dicentrarchus labrax) during the annual cycle: Roles of environmental temperature and salinity. Comp. Biochem. Physiol. B 2002, 133, 281-288.
14. Henriques, J., Dick, J. R., Tocher, D. R., Bell, J. G., Nutritional quality of salmon products available from major retailers in the UK: Content and composition of n-3 long-chain PUFA. Brit. J. Nutr. 2014, 14, 1-12.
15. Meyer, B. J., Mann, N. J., Lewis, J. L., Milligan, G. C., et al., Dietary intakes and food sources of omega-6 and omega-3 polyunsaturated fatty acids. Lipids 2003, 38, 391-398.
16. Howe, P., Meyer, B., Record, S., Baghurst, K., Dietary intake of long-chain omega-3 polyunsaturated fatty acids: Contribution of meat sources. Nutrition 2006, 22, 47-53.
17. Rahmawaty, S., Charlton, K., Lyons-Wall, P., Meyer, B. J., Dietary intake and food sources of EPA, DPA and DHA in Australian children. Lipids 2013, 48, 869-877.
18. Stubbs, C. D., Smith, A. D., The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fuidity and function. Biochim. Biophys. Acta 1984, 779, 89-137.
19. Brenner, R. R., Effect of unsaturated fatty acids on membrane structure and enzyme kinetics. Prog. Lipid Res. 1984, 23, 69-96.
20. Murphy, M. G., Dietary fatty acids and membrane protein function. J. Nutr. Biochem. 1990, 1, 68-79.
21. Browning, L. M., Walker, C. G., Mander, A. P., West, A. L., et al., Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. Am. J. Clin. Nutr. 2012, 96, 748-758.
22. Skinner, E. R., Watt, C., Besson, J. A., Best, P. V., Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimer's disease and control subjects. Brain 1993, 116, 717-725.
23. Makrides, M., Neumann, M. A., Byard, R. W., Simmer, K., Gibson, R. A., Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-fed infants. Am. J. Clin. Nutr. 1994, 60, 189-194.
24. Crawford, M. A., Casperd, N. M., Sinclair, A. J., The long chain metabolites of linoleic and linolenic acids in liver and brain in herbivores and carnivores. Comp. Biochem. Physiol. B 1976, 54, 395-401.
25. Anderson, R. E., Lipids of ocular tissues. IV. A comparison of the phospholipids from the retina of six mammalian species. Exp. Eye Res. 1970, 10, 339-344.
26. von Schacky, C., Fischer, S., Weber, P. C., Long term effects of dietary marine ω-3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans. J. Clin. Invest. 1985, 76, 1626-1631.
27. Harris, W. S., Windsor, S. L., Dujovne, C. A., Effects of four doses of n-3 fatty acids given to hyperlipidemic patients for six months. J. Am. Coll. Nutr. 1991, 10, 220-227.
28. Marsen, T. A., Pollok, M., Oette, K., Baldamus, C. A., Pharmacokinetics of omega-3 fatty acids during ingestion of fish oil preparations. Prostagl. Leukotr. Essent. Fatty Acids 1992, 46, 191-196.
29. Blonk, M. C., Bilo, H. J., Popp-Snijders, C., Mulder, C., Donker, A. J., Dose-response effects of fish oil supplementation in healthy volunteers. Am. J. Clin. Nutr. 1990, 52, 120-127.
30. Katan, M. B., Deslypere, J. P., van Birgelen, A. P. J. M., Penders, M., Zegwaars, M., Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes and adipose tissue: An 18 month controlled study. J. Lipid Res. 1997, 38, 2012-2022.
31. Yaqoob, P., Pala, H. S., Cortina-Borja, M., Newsholme, E. A., Calder, P. C., Encapsulated fish oil enriched in α-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions. Eur. J. Clin. Invest. 2000, 30, 260-274.
32. Rees, D., Miles, E. A., Banerjee, T., Wells, S. J., et al., Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: A comparison of young and older men. Am. J. Clin. Nutr. 2006, 83, 331-342.
33. Faber, J., Berkhout, M., Vos, A. P., Sijben, J. W., et al., Supplementation with a fish oil-enriched, high-protein medical food leads to rapid incorporation of EPA into white blood cells and modulates immune responses within one week in healthy men and women. J. Nutr. 2011, 141, 964-970.
34. Popp-Snijders, C., Schouten, J. A., van Blitterswijk, W. J., van der Veen, E. A., Changes in membrane lipid composition of human erythrocytes after dietary supplementation of (n-3) fatty acids: Maintenance of membrane fluidity. Biochim. Biophys. Acta 1986, 854, 31-37.
35. Sanders, T. A. B., Roshanai, F., The influence of different types of ω3 polyunsaturated fatty acids on blood lipids and platelet function in healthy volunteers. Clin. Sci. 1983, 64, 91-99.
36. Healy, D. A., Wallace, F. A., Miles, E. A., Calder, P. C., Newsholme, P., The effect of low to moderate amounts of dietary fish oil on neutrophil lipid composition and function. Lipids 2000, 35, 763-768.
37. Sperling, R. I., Benincaso, A. I., Knoell, C. T., Larkin, J. K., et al., Dietary ω-3 polyunsaturated fatty acids inhibit phosphoinositide formation, and chemotaxis in neutrophils. J. Clin. Invest. 1993, 91, 651-660.
38. McGlory, C., Galloway, S. D., Hamilton, D. L., McClintock, C., et al., Temporal changes in human skeletal muscle and blood lipid composition with fish oil supplementation. Prostagland. Leukotr. Essent. Fatty Acids 2014, 90, 199-206.
39. Harris, W. S., Sands, S. A., Windsor, S. L., Ali, H. A., et al., Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: Correlation with erythrocyes and response to supplementation. Circulation 2004, 110, 1645-1649.
40. Hillier, K., Jewell, R., Dorrell, L., Smith, C. L., Incorporation of fatty acids from fish oil and olive oil into colonic mucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease. Gut 1991, 32, 1151-1155.
41. Sorensen, L. S., Rasmussen, H. H., Aardestrup, I. V., Thorlacius-Ussing, O., et al., Rapid incorporation of ω-3 fatty acids into colonic tissue after oral supplementation in patients with colorectal cancer: A randomized, placebo-controlled intervention trial. J. Parent. Ent. Nutr. 2014, 38, 617-624.
42. Calder, P. C., Mechanisms of action of (n-3) fatty acids. J. Nutr. 2012, 142, 592S-599S.
43. Calder, P. C., Omega-3 polyunsaturated fatty acids and inflammatory processes: Nutrition or pharmacology? Brit. J. Clin. Pharmacol. 2013, 75, 645-662.
44. Calder, P. C., n-3 Fatty acids, inflammation and immunity: New mechanisms to explain old actions. Proc. Nutr. Soc. 2013, 72, 326-336.
45. Calder, P. C., Yaqoob, P., Harvey, D. J., Watts, A., Newsholme, E. A., The incorporation of fatty acids by lymphocytes and the effect on fatty acid composition and membrane fluidity. Biochem. J. 1994, 300, 509-518.
46. Miles, E. A., Calder, P. C., Modulation of immune function by dietary fatty acids. Proc. Nutr. Soc. 1998, 57, 277-292.
47. Pike, L. J., Lipid rafts: Bringing order to chaos. J. Lipid Res. 2003, 44, 655-667.
48. Simons, K., Gerl, M. J., Revitalizing membrane rafts: New tools and insights. Nat. Rev. Mol. Cell. Biol. 2010, 11, 688-699.
49. Yaqoob, P., The nutritional significance of lipid rafts. Annu. Rev. Nutr. 2009, 29, 257-282.
50. Calder, P. C., Yaqoob, P., Lipid rafts - Composition, characterization and controversies. J. Nutr. 2007, 137, 545-547.
51. Calder, P. C., Fat chance to enhance B cell function. J. Leuk. Biol. 2013, 93, 457-459.
52. Calder, P. C., Long chain fatty acids and gene expression in inflammation and immunity. Curr. Opin. Clin. Nutr. Metab. Care 2013, 16, 425-433.
53. Novak, T. E., Babcock, T. A., Jho, D. H., Helton, W. S., Espat, N. J., NF-kappa B inhibition by omega-3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am. J. Physiol. 2003, 284, L84-L89.
54. Gottlicher, M., Widmaek, E., Li, Q., Gustafsson, J.-A., Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc. Natl. Acad. Sci. USA 1992, 89, 4653-4657.
55. Krey, G., Braissant, O., L'Horset, F., Kalkhoven, E., et al., Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 1997, 11, 779-791.
56. Clarke, S. D., The multi-dimensional regulation of gene expression by fatty acids: Polyunsaturated fats as nutrient sensors. Curr. Opin. Lipidol. 2004, 15, 13-18.
57. Lapillonne, A., Clarke, S. D., Heird, W. C., Polyunsaturated fatty acids and gene expression. Curr. Opin. Clin. Nutr. Metab. Care 2004, 7, 151-156.
58. Jump, D. B., Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr. Opin. Lipidol. 2002, 13, 155-164.
59. Jump, D. B., N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Curr. Opin. Lipidol. 2008, 19, 242-247.
60. Deckelbaum, R. J., Worgall, T. S., Seo, T., N-3 fatty acids and gene expression. Am. J. Clin. Nutr. 2006, 83, 1520S-1525S.
61. Lewis, R. A., Austen, K. F., Soberman, R. J., Leukotrienes and other products of the 5-lipoxygenase pathway: Biochemistry and relation to pathobiology in human diseases. N. Engl. J. Med. 1990, 323, 645-655.
62. Tilley, S. L., Coffman, T. M., Koller, B. H., Mixed messages: Modulation of inflammation and immune responses by prostaglandins and thromboxanes. J. Clin. Invest. 2001, 108, 15-23.
63. Wada, M., DeLong, C. J., Hong, Y. H., Rieke, C. J., et al., Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J. Biol. Chem. 2007, 282, 22254-22266.
64. Moncada, S., Vane, J. R., The role of prostacyclin in vascular tissue. Fed. Proc. 1979, 38, 68-71.
65. Bannenberg, G., Serhan, C. N., Specialized pro-resolving lipid mediators in the inflammatory response: An update. Biochim. Biophys. Acta 2010, 1801, 1260-1273.
66. Serhan, C. N., Yacoubian, S., Yang, R., Anti-inflammatory and proresolving lipid mediators. Annu. Rev. Pathol. 2008, 3, 279-312.
67. Serhan, C. N., Chiang, N., van Dyke, T. E., Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 2008, 8, 349-361.
68. Dalli, J., Colas, R. A., Serhan, C. N., Novel n-3 immunoresolvents: Structures and roles. Sci. Rep. 2013, 3, 1940.
69. Oh, D. Y., Talukdar, S., Bae, E. J., Imamura, T., et al., GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010, 142, 687-698.
70. Nettleton, J. A., Omega-3 Fatty Acids and Health. Chapman and Hall, New York 1995.
71. Watson, R. A., Fatty Acids in Health Promotion and Disease Causation. AOCS Press, Urbana, IL 2009.
72. Dyerberg, J., Bang, H. O., Stoffersen, E., Moncada, S., Vane, J. R., Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis. Lancet 1978, 2, 117-119.
73. Kromann, N., Green, A., Epidemiological studies in the Upernavik District, Greenland. Acta Med. Scand. 1980, 208, 401-406.
74. Bjerregaard, P., Dyerberg, J., Mortality from ischemic heart disease and cerebrovascular disease in Greenland. Int. J. Epidemiol. 1988, 17, 514-519.
75. Newman, W. P., Middaugh, J. P., Propst, M. T., Rogers, D. R., Atherosclerosis in Alaska natives and non-natives. Lancet 1993, 341, 1056-1057.
76. Bang, H. O., Dyerberg, J., Hjorne, N., The composition of foods consumed by Greenland Eskimos. Acta Med. Scand. 1976, 200, 69-73.
77. Yano, K., MacLean, C. J., Reed, D. M., Shimizu, Y., et al., A comparison of the 12-year mortality and predictive factors of coronary heart disease among Japanese men in Japan and Hawaii. Am. J. Epidemiol. 1988, 127, 476-487.
78. Kris-Etherton, P. M., Harris, W. S., Appel, L. J., Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. American Heart Association Nutrition Committee. Circulation 2002, 106, 2747-2757.
79. von Schacky, C., Omega-3 fatty acids and cardiovascular disease. Curr. Opin. Clin. Nutr. Metab. Care 2004, 7, 131-136.
80. London, B., Albert, C., Anderson, M., Giles, W. R., et al., Omega-3 fatty acids and cardiac arrhythmias: Prior studies and recommendations for future research: A report from the National Heart, Lung, and Blood Institute and Office Of Dietary Supplements Omega-3 Fatty Acids and their Role in Cardiac Arrhythmogenesis Workshop. Circulation 2007, 116, e320-e335.
81. Wang, C., Harris, W. S., Chung, M., Lichtenstein, A. H., et al., n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: A systematic review. Am. J. Clin. Nutr. 2006, 84, 5-17.
82. Calder, P. C., n-3 fatty acids and cardiovascular disease: Evidence explained and mechanisms explored. Clin. Sci. 2004, 107, 1-11.
83. Chowdhury, R., Warnakula, S., Kunutsor, S., Crowe, F., et al., Association of dietary, circulating, and supplement fatty acids with coronary risk: A systematic review and meta-analysis. Ann. Intern. Med. 2014, 160, 398-406.
84. Harris, W. S., N-3 fatty acids and lipoproteins: Comparison of results from human and animal studies. Lipids 1996, 31, 243-252.
85. Saravanan, P., Davidson, N. C., Schmidt, E. B., Calder, P. C., Cardiovascular effects of marine omega-3 fatty acids. Lancet 2010, 376, 540-550.
86. De Caterina, R., n-3 fatty acids in cardiovascular disease. N. Engl. J. Med. 2011, 364, 2439-2450.
87. Burr, M. L., Fehily, A. M., Gilbert, J. F., Rogers, S., et al., Effects of changes in fat, fish and fibre intake on death and myocardial reinfarction: Diet and reinfarction trial (DART). Lancet 1989, 2, 757-761.
88. Anonymous, Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Lancet 1999, 354, 447-455.
89. GISSI-Prevenzione Investigators. Marchioli, R., Barzi, F., Bomba, E., Chieffo, C., et al., Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002, 105, 1897 -1903.
90. Japan EPA lipid intervention study (JELIS) Investigators. Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., et al., Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007, 369, 1090-1098.
91. Gissi-HF Investigators. Tavazzi, L., Maggioni, A. P., Marchioli, R., Barlera, S., et al., Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008, 372, 1223-1230.
92. Bucher, H. C., Hengstler, P., Schindler, C., Meier, G., N-3 polyunsaturated fatty acids in coronary heart disease: A meta-analysis of randomized controlled trials. Am. J. Med. 2002, 112, 298-304.
93. Studer, M., Briel, M., Leimenstoll, B., Glass, T. R., Bucher, H. C., Effect of different antilipidemic agents and diets on mortality: A systematic review. Arch. Intern. Med. 2005, 165, 725-730.
94. Leon, H., Shibata, M. C., Sivakumaran, S., Dorgan, M., et al., Effect of fish oil on arrhythmias and mortality: Systematic review. Brit. Med. J. 2009, 338, a2931.
95. Harris, W. S., Miller, M., Tighe, A. P., Davidson, M. H., Schaefer, E. J., Omega-3 fatty acids and coronary heart disease risk: Clinical and mechanistic perspectives. Atherosclerosis 2008, 197, 12-24.
96. Xin, W., Wei, W., Li, X. Y., Short-term effects of fish-oil supplementation on heart rate variability in humans: A meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 2013, 97, 926-935.
97. Leaf, A., Xiao, Y. F., The modulation of ionic currents in excitable tissues by n-3 polyunsaturated fatty acids. J. Memb. Biol. 2001, 184, 263-271.
98. Thies, F., Garry, J. M. C., Yaqoob, P., Rerkasem, K., et al., Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: A randomised controlled trial. Lancet 2003, 361, 477-485.
99. Cawood, A. L., Ding, R., Napper, F. L., Young, R. H., et al., Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis 2010, 212, 252-259.
100. Calder, P. C., Yaqoob, P., Omega-3 (n-3) fatty acids, cardiovascular disease and stability of atherosclerotic plaques. Cell. Mol. Biol. 2010, 56, 28-37.
101. SU.FOL.OM3 Collaborative Group. Galan, P., Kesse-Guyot, E., Czernichow, S., Briancon, S., et al., Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: A randomised placebo controlled trial. BMJ 2010, 341, c6273.
102. Alpha Omega Trial Group. Kromhout, D., Giltay, E. J., Geleijnse, J. M., n-3 fatty acids and cardiovascular events after myocardial infarction. N. Engl. J. Med. 2010, 363, 2015-2026.
103. OMEGA Study Group. Rauch, B., Schiele, R., Schneider, S., Diller, F., et al., OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010, 122, 2152-2159.
104. Risk and Prevention Study Collaborative Group. Roncaglioni, M. C., Tombesi, M., Avanzini, F., Barlera, S., et al., n-3 fatty acids in patients with multiple cardiovascular risk factors. N. Engl. J. Med. 2013, 368, 1800-1808.
105. ORIGIN Trial Investigators. Bosch, J., Gerstein, H. C., Dagenais, G. R., Diaz, R., et al., n-3fatty acids and cardiovascular outcomes in patients with dysglycemia. N. Engl. J. Med. 2012, 367, 309-318.
106. Korean Meta-analysis Study Group. Kwak, S. M., Myung, S. K., Lee, Y. J., Seo, H. G., Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: A meta-analysis of randomized, double-blind, placebo-controlled trials. Arch. Intern. Med. 2012, 172, 686-694.
107. Kotwal, S., Jun, M., Sullivan, D., Perkovic, V., Neal, B., Omega 3 Fatty acids and cardiovascular outcomes: Systematic review and meta-analysis. Circ. Cardiovasc. Qual. Outcomes 2012, 5, 808-818.
108. Rizos, E. C., Ntzani, E. E., Bika, E., Kostapanos, M. S., Elisaf, M. S., Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: A systematic review and meta-analysis. J. Am. Med. Assoc. 2012, 308, 1024-1033.
109. Calder, P. C., Yaqoob, P., Marine omega-3 fatty acids and coronary heart disease. Curr. Opin. Cardiol. 2012, 27, 412-419.
110. Casula, M., Soranna, D., Catapano, A. L., Carrao, G., Long-term effect of high dose omega-3 fatty acidsupplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, double blind, placebo controlled trials. Atheroscler. Suppl. 2013, 14, 243-251.
111. Wen, Y. T., Dai, J. H., Gao, Q., Effects of omega-3 fatty acid on major cardiovascular events and mortality in patients with coronary heart disease: A meta-analysis of randomized controlled trials. Nutr. Metab. Cardiovasc. Dis. 2014, 24, 470-475.
112. Gleissman, H., Johnsen, J. I., Kogner, P., Omega-3 fatty acids in cancer, the protectors of good and the killers of evil? Exp. Cell Res. 2010, 316, 1365-1373.
113. Merendino, N., Costantini, L., Manzi, L., Molinari, R., et al., Dietary ω-3 polyunsaturated fatty acids DHA: A potential adjuvant in the treatment of cancer. BioMed. Res. Int. 2013, 310186.
114. Wang, D., Dubois, R. N., Eicosanoids and cancer. Nat. Rev. Cancer 2010, 10, 181-193.
115. Vaughan, V. C., Hassing, M. R., Lewandowski, P. A., Marine polyunsaturated fatty acids and cancer therapy. Brit. J. Cancer 2013, 108, 486-492.
116. Murphy, R. A., Mourtzakis, M., Mazurak, V. C., n-3 polyunsaturated fatty acids: The potential role for supplementation in cancer. Curr. Opin. Clin. Nutr. Metab. Care 2012, 15, 246-251.
117. Gerber, M., Omega-3 fatty acids and cancers: A systematic update review of epidemiological studies. Brit. J. Nutr. 2012, 107 (Suppl 2), S2228-S2239.
118. Makarem, N., Chandran, U., Bandera, E. V., Parekh, N., Dietary fat in breast cancer survival. Annu. Rev. Nutr. 2013, 33, 319-348.
119. Sczaniecka, A. K., Brasky, T. M., Lampe, J. W., Patterson, R. E., White, E., Dietary intake of specific fatty acids and breast cancer risk among postmenopausal women in the VITAL cohort. Nutr. Cancer 2012, 64, 1131-1142.
120. Elia, M., Van Bokhorst-de van der Schueren, M. A., Garvey, J., Goedhart, A., et al., Enteral (oral or tube administration) nutritional support and eicosapentaenoic acid in patients with cancer: A systematic review. Int. J. Oncol. 2006, 28, 5-23.
121. Alfano, C. M., Imayama, I., Neuhouser, M. L., Kiecolt-Glaser, J. K., et al., Fatigue, inflammation, and ω-3 and ω-6 fatty acid intake among breast cancer survivors. J. Clin. Oncol. 2012, 30, 1280-1287.
122. Cerchietti, L. C., Navigante, A. H., Castro, M. A., Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr. Cancer 2007, 59, 14-20.
123. van der Meij, B. S., Langius, J. A., Spreeuwenberg, M. D., Slootmaker, S. M., et al., Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: An RCT. Eur. J. Clin. Nutr. 2012, 66, 399-404.
124. Sala-Vila, A., Folkes, J., Calder, P. C., The effect of three lipid emulsions differing in fatty acid composition on growth, apoptosis and cell cycle arrest in the HT-29 colorectal cancer cell line. Clin. Nutr. 2010, 29, 519-524.
125. Murphy, R. A., Mourtzakis, M., Chu, Q. S., Baracos, V. E., et al., Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer 2011, 117, 3774-3780.
126. Bougnoux, P., Hajjaji, N., Ferrasson, M. N., Giraudeau, B., et al., Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: A phase II trial. Brit. J. Cancer 2009, 101, 1978 -1985.
127. Weed, H. G., Ferguson, M. L., Gaff, R. L., Hustead, D. S., et al., Lean body mass gain in patients with head and neck squamous cell cancer treated perioperatively with a protein- and energy-dense nutritional supplement containing eicosapentaenoic acid. Head Neck 2011, 33, 1027-1033.
128. Murphy, R. A., Mourtzakis, M., Chu, Q. S., Baracos, V. E., et al., Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer 2011, 117, 1775-1782.
129. Fearon, K. C., Barber, M. D., Moses, A. G., Ahmedzai, S. H., et al., Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J. Clin. Oncol. 2006, 24, 3401-3407.
130. Guarcello, M., Riso, S., Buosi, R., d'Andrea, F., EPA-enriched oral nutritional support in patients with lung cancer: Effects on nutritional status and quality of life. Nutr. Therap. Metab. 2007, 25, 25-30.
131. Calder, P. C., Fatty acids and inflammation: The cutting edge between food and pharma. Eur. J. Pharmacol. 2011, 668 (Suppl 1), S50-S58.
132. Calder, P. C., Albers, R., Antoine, J. M., Blum, S., et al., Inflammatory disease processes and interactions with nutrition. Brit. J. Nutr. 2009, 101 (Suppl 1), S1-45.
133. Calder, P. C., Ahluwalia, N., Albers, R., Bosco, N., et al., A consideration of biomarkers to be used for evaluation of inflammation in human nutritional studies. Brit. J. Nutr. 2013, 109 (Suppl 1), S1-S34.
134. Ross, R., Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999, 340, 115-126.
135. Hansson, G. K., Hermansson, A., The immune system in atherosclerosis. Nat. Immunol. 2011, 12, 204-212.
136. Calder, P. C., Ahluwalia, N., Brouns, F., Buetler, T., et al., Dietary factors and low-grade inflammation in relation to overweight and obesity. Brit. J. Nutr. 2011, 106 (Suppl 3), S5-S78.
137. Miles, E. A., Calder, P. C., Influence of marine n-3 polyunsaturated fatty acids on immune function and a systematic review of their effects on clinical outcomes in rheumatoid arthritis. Brit. J. Nutr. 2012, 107 (Suppl 2), S171-S184.
138. Calder, P. C., Fatty acids and immune function: Relevance to inflammatory bowel diseases. Int. Rev. Immunol. 2009, 28, 506-534.
139. Calder, P. C., n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am. J. Clin. Nutr. 2006, 83, 1505S-1519S.
140. Calder, P. C., Kremmyda, L. S., Vlachava, M., Noakes, P. S., Miles, E. A., Is there a role for fatty acids in early life programming of the immune system? Proc. Nutr. Soc. 2010, 69, 373-380.
141. Calder, P. C., Fishing for allergy prevention. Clin. Exp. Allergy 2013, 43, 700-702.
142. Haggarty, P., Fatty acid supply to the human fetus. Annu. Rev. Nutr. 2010, 30, 237-255.
143. Swanson, D., Block, R., Mousa, S. A., Omega-3 fatty acids EPA and DHA: Health benefits throughout life. Adv. Nutr. 2012, 3, 1-7.
144. Dunstan, J. A., Mori, T. A., Barden, A., Beilin, L. J., et al., Maternal fish oil supplementation in pregnancy reduces interleukin-13 levels in cord blood of infants at high risk of atopy. Clin. Exp. Allergy 2003, 33, 442-448.
145. Dunstan, J. A., Mori, T. A., Barden, A., Beilin, L. J., et al., Fish oil supplementation in pregnancy modifies neonatal allergen-specific immune responses and clinical outcomes in infants at high risk of atopy: A randomized, controlled trial. J. Allergy Clin. Immunol. 2003, 112, 1178-1184.
146. Noakes, P. S., Vlachava, M., Kremmyda, L. S., Diaper, N. D., et al., Increased intake of oily fish in pregnancy: Effects on neonatal immune responses and on clinical outcomes in infants at 6 mo. Am. J. Clin. Nutr. 2012, 95, 395-404.
147. Furuhjelm, C., Warstedt, K., Larsson, J., Fredriksson, M., et al., Fish oil supplementation in pregnancy and lactation may decrease the risk of infant allergy. Acta Paediatr. 2009, 98, 1461-1467.
148. Palmer, D. J., Sullivan, T., Gold, M. S., Prescott, S. L., et al., Effect of n-3 long chain polyunsaturated fatty acid supplementation in pregnancy on infants' allergies in first year of life: Randomised controlled trial. Brit. Med. J. 2012, 344, e184.
149. D'Vaz, N., Meldrum, S. J., Dunstan, J. A., Lee-Pullen, T. F., et al., Fish oil supplementation in early infancy modulates developing infant immune responses. Clin. Exp. Allergy 2012, 42, 1206-1216.
150. Lauritzen, L., Hansen, H. S., Jorgensen, M. H., Michaelsen, K. F., The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. Prog. Lipid Res. 2001, 40, 1-94.
151. Salem, N., Litman, B., Kim, H. Y., Gawrisch, K., Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 2001, 36, 945-959.
152. Parletta, N., Milte, C. M., Meyer, B. J., Nutritional modulation of cognitive function and mental health. J. Nutr. Biochem. 2013, 24, 725-743.
153. Uauy, R. D., Birch, D. G., Birch, E. E., Tyson, J. E., Hoffman, D. R., Effect of dietary omega-3 fatty acids on retinal function of very-low-birth-weight neonates. Pediatr. Res. 1990, 28, 485-492.
154. Birch, D. G., Birch, E. E., Hoffman, D. R., Uauy, R. D., Retinal development in very-low-birth-weight infants fed diets differing in omega-3 fatty acids. Invest. Opthalmol. Vis. Sci. 1992, 33, 2365-2376.
155. Birch, E. E., Birch, D. G., Hoffman, D. R., Uauy, R., Dietary essential fatty acid supply and visual acuity development. Invest. Opthalmol. Vis. Sci. 1992, 33, 3242-3253.
156. Carlson, S. E., Werkman, S. H., Rhodes, P. G., Tolley, E. A., Visual acuity development in healthy preterm infants: Effect of marine oil supplementation. Am. J. Clin. Nutr. 1993, 58, 35-42.
157. Carlson, S. E., Ford, A. J., Werkman, S. H., Peeples, J. M., Koo, W. W., Visual acuity and fatty acid status of term infants fed human milk and formulas with and without docosahexaenoate and arachidonate from egg yolk lecithin. Pediatr. Res. 1996, 39, 882-888.
158. Carlson, S. E., Werkman, S. H., Tolley, E. A., Effect of long-chain n-3 fatty acid supplementation on visual acuity and growth of preterm infants with and without bronchopulmonary dysplasia. Am. J. Clin. Nutr. 1996, 63, 687-697.
159. Schulzke, S. M., Patole, S. K., Simmer, K., Long-chain polyunsaturated fatty acid supplementation in preterm infants. Cochrane Database Syst. Rev. 2011, 2, CD000375.
160. Molloy, C., Doyle, L. W., Makrides, M., Anderson, P. J., Docosahexaenoic acid and visual functioning in preterm infants: A review. Neuropsychol. Rev. 2012, 22, 425-437.
161. Agostoni, C., Trojan, S., Bellu, R., Riva, E., Giovannini, M., Neurodevelopmental quotient of healthy term infants at 4 months and feeding practice: The role of long-chain polyunsaturated fatty acids. Pediatr. Res. 1995, 38, 262-266.
162. Willatts, P., Forsyth, J. S., DiModugno, M. K., Varma, S., Colvin, M., Effect of long-chain polyunsaturated fatty acids in infant formula on problem solving at 10 months of age. Lancet 1998, 352, 688-691.
163. Scott, D. T., Janowsky, J. S., Carroll, R. E., Taylor, J. A., et al., Formula supplementation with long-chain polyunsaturated fatty acids: Are there developmental benefits? Pediatrics 1998, 102, E59.
164. Makrides, M., Neumann, M. A., Simmer, K., Gibson, R. A., A critical appraisal of the role of dietary long-chain polyunsaturated fatty acids on neural indices of term infants: A randomized, controlled trial. Pediatrics 2000, 105, 32-38.
165. Auested, N., Halter, R., Hall, R. T., Blatter, M., et al., Groeth and development of term infants fed long-chain polyunsaturated fatty acids: A double-masked, randomized, parallel, prospective, multivariate study. Pediatrics 2001, 108, 272-381.
166. Auested, N., Scott, D. T., Janowsky, J. S., Jacobsen, C., et al., Visual, cognitive, and language assessments at 39 months: A follow-up study of children fed formulas containing long-chain polyunsaturated fatty acids to 1 year of age. Pediatrics 2003, 112, e177-e183.
167. Agostoni, C., Trojan, S., Bellu, R., Riva, E., et al., Developmental quotient at 24 months and fatty acid composition of diet in early infancy: A follow up study. Arch. Dis. Child. 1997, 76, 421-424.
168. Simmer, K., Patole, S. K., Rao, S. C., Long-chain polyunsaturated fatty acid supplementation in infants born at term. Cochrane Database Syst. Rev. 2011, 12, CD000376.
169. Gould, J. F., Smithers, L. G., Makrides, M., The effect of maternal omega-3 (n-3) LCPUFA supplementation during pregnancy on early childhood cognitive and visual development; a systematic review and meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 2013, 97, 531-544.
170. Richardson, A. J., Clinical trials of fatty acid treatment in ADHD, dyslexia, dyspraxia and the autistic spectrum. Prostagl. Leuk. Essent. Fatty Acids 2004, 70, 383-390.
171. Stevens, L., Zhang, W., Peck, L., Kuczek, T., et al., EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids 2003, 38, 1007-1021.
172. Richardson, A. J., Puri, B. K., A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog. Neuropsychopharmacol. Biol. Psych. 2002, 26, 233-239.
173. Yui, K., Koshiba, M., Nakamura, S., Kobayashi, Y., Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: A double-blind, placebo-controlled, randomized trial. J. Clin. Psychopharmacol. 2012, 32, 200-206.
174. Meguid, N. A., Atta, H. M., Gouda, A. S., Khalil, R. O., Role of polyunsaturated fatty acids in the management of Egyptian children with autism. Clin. Biochem. 2008, 41, 1044-1048.
175. Perera, H., Jeewandara, K. C., Seneviratne, S., Guruge, C., Combined ω3 and ω6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: A double-blind, placebo-controlled study. J. Child. Neurol. 2012, 27, 747-753.
176. Milte, C. M., Parletta, N., Buckley, J. D., Coates, A. M., et al., Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: A randomized controlled trial. Nutrition 2012, 28, 670-677.
177. Gustafsson, P. A., Birberg-Thornberg, U., Duchén, K., Landgren, M., et al., EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatr. 2010, 99, 1540-1549.
178. Bélanger, S. A., Vanasse, M., Spahis, S., Sylvestre, M. P., et al., Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: A randomized, double-blind, placebo-controlled study. Paediatr. Child Health 2009, 14, 89-98.
179. Sorgi, P. J., Hallowell, E. M., Hutchins, H. L., Sears, B., Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder. Nutr. J. 2007, 6, 16.
180. Voigt, R. G., Llorente, A. M., Jensen, C. L., Fraley, J. K., et al., A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J. Pediatr. 2001, 139, 189-196.
181. Hirayama, S., Hamazaki, T., Terasawa, K., Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder-a placebo-controlled double-blind study. Eur. J. Clin. Nutr. 2004, 58, 467-473.
182. Bent, S., Bertoglio, K., Ashwood, P., Bostrom, A., Hendren, R. L., A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder. J. Autism Dev. Disord. 2011, 41, 545-554.
183. Politi, P., Cena, H., Comelli, M., Marrone, G., et al., Behavioral effects of omega-3 fatty acid supplementation in young adults with severe autism: An open label study. Arch. Med. Res. 2008, 39, 682-685.
184. Amminger, G. P., Berger, G. E., Schäfer, M. R., Klier, C., et al., Omega-3 fatty acids supplementation in children with autism: A double-blind randomized, placebo-controlled pilot study. Biol. Psychiatry 2007, 61, 551-553.
185. Johnson, M., Ostlund, S., Fransson, G., Kadesjö, B., Gillberg, C., Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: A randomized placebo-controlled trial in children and adolescents. J. Atten. Disord. 2009, 12, 394-401.
186. Raz, R., Carasso, R. L., Yehuda, S., The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: A double-blind placebo-controlled study. J. Child Adolesc. Psychopharmacol. 2009, 19, 167-177.
187. Frensham, L. J., Bryan, J., Parletta, N., Influences of micronutrient and omega-3 fatty acid supplementation on cognition, learning, and behaviour: Methodological considerations and implications for children and adolescents in developed societies. Nutr. Rev. 2012, 70, 594-610.
188. Rudin, D. O., The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome: Substrate pellagra. Biol. Psychiatry 1981, 16, 837-850.
189. Peet, M., Laugharne, J., Rangarajan, N., Horrobin, D., Reynolds, G., Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J. Psychiatr. Res. 1995, 29, 227-232.
190. Yao, J. K., van Kammen, D. P., Welker, J. A., Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr. Res. 1994, 13, 217-226.
191. Glen, A. I., Glen, E. M., Horrobin, D. F., Vaddadi, K. S., et al., A red cell membrane abnormality in a subgroup of schizophrenic patients: Evidence for two diseases. Schizophr. Res. 1994, 12, 53-61.
192. Edwards, R., Peet, M., Shay, J., Horrobin, D., Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J. Affect. Disord. 1998, 48, 149-155.
193. Hibbeln, J. R., Fish consumption and major depression. Lancet 1998, 351, 1213.
194. Su, K. P., Huang, S. Y., Chiu, C. C., Shen, W. W., Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur. Neuropsychopharmacol. 2003, 13, 267-271.
195. Marangell, L. B., Martinez, J. M., Zboyan, H. A., Kertz, B., et al., A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am. J. Psychiatry 2003, 160, 996-998.
196. Stoll, A. L., Severus, W. E., Freeman, M. P., Rueter, S., et al., Omega 3 fatty acids in bipolar disorder: A preliminary double-blind, placebo-controlled trial. Arch. Gen. Psychiatry 1999, 56, 407-412.
197. Nemets, B., Stahl, Z., Belmaker, R. H., Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am. J. Psychiatry 2002, 159, 477-479.
198. Peet, M., Brind, J., Ramchand, C. N., Shah, S., Vankar, G. K., Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr. Res. 2001, 49, 243-251.
199. Peet, M., Horrobin, D. F., A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch. Gen. Psychiatry 2002, 59, 913-919.
200. Fenton, W. S., Dickerson, F., Boronow, J., Hibbeln, J. R., Knable, M., A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am. J. Psychiatry 2001, 158, 2071-2074.
201. Emsley, R., Myburgh, C., Oosthuizen, P., van Rensburg, S. J., Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am. J. Psychiatry 2002, 159, 1596-1598.
202. Joy, C. B., Mumby-Croft, R., Joy, L. A., Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst. Rev. 2003, 2, CD001257.
203. Zanarini, M. C., Frankenburg, F. R., N-3 fatty acid treatment of women with borderline personality disorder: A double-blind, placebo-controlled pilot study. Am. J. Psychiatry 2003, 160, 167-169.
204. Hamazaki, T., Sawazaki, S., Itomura, M., Asaoka, E., et al., The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study. J. Clin. Invest. 1996, 97, 1129-1133.
205. Hamazaki, T., Thienprasert, A., Kheovichai, K., Samuhaseneetoo, S., et al., The effect of docosahexaenoic acid on aggression in elderly Thai subjects-a placebo-controlled double-blind study. Nutr. Neurosci. 2002, 5, 37-41.
206. Sublette, M. E., Ellis, S. P., Geant, A. L., Mann, J. J., Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J. Clin. Psychiatry 2012, 72, 1577-1584.
207. Sarris, J., Mischoulon, D., Schweitzer, I., Omega-3 for bipolar disorder: Meta-analyses of use in mania and bipolar depression. J. Clin. Psychiatry 2012, 73, 81-86.
208. Prasad, M. R., Lovell, M. A., Yatin, M., Dhillon, H., Markesbery, W. R., Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res. 1998, 23, 81-88.
209. Tully, A. M., Roche, H. M., Doyle, R., Fallon, C., et al., Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: A case-control study. Brit. J. Nutr. 2003, 89, 483-489.
210. Cunnane, S. C., Schneider, J. A., Tangney, C., Morris, M. C., Plasma and brain fatty acid profile in mild cognitive impairment and Alzheimer's disease. J. Alzheimers Dis. 2012, 29, 691-697.
211. Soderberg, M., Edlund, C., Kristensson, K., Dallner, G., Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 1991, 26, 421-425.
212. Conquer, J. A., Tierney, M. C., Zecevic, J., Bettger, W. J., Fisher, R. H., Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids 2000, 35, 1305-1312.
213. Sydenham, E., Dangour, A. D., Lim, W. S., Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database Syst. Rev. 2012, 6, CD005379.
214. Sinn, N., Milte, C. M., Street, S. J., Buckley, J. D., et al., Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: A 6-month randomised controlled trial. Brit. J. Nutr. 2012, 107, 1682-1693.
215. Scheltens, P., Twisk, J. W., Blesa, R., Scarpini, E., et al., Efficacy of Souvenaid in mild Alzheimer's disease: Results from a randomized, controlled trial. J. Alzheimers Dis. 2012, 31, 225-236.
216. Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., et al., Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: A randomized trial. J. Am. Med. Assoc. 2010, 304, 1903-1911.
217. Freund-Levi, Y., Eriksdotter-Jönhagen, M., Cederholm, T., Basun, H., et al., Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: A randomized double-blind trial. Arch. Neurol. 2006, 63, 1402-1408.
218. Freund-Levi, Y., Basun, H., Cederholm, T., Faxén-Irving, G., et al., Omega-3 supplementation in mild to moderate Alzheimer's disease: Effects on neuropsychiatric symptoms. Int. J. Geriatr. Psychiatry 2008, 23, 161-169.
219. Kotani, S., Sakaguchi, E., Warashina, S., Matsukawa, N., et al., Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci. Res. 2006, 56, 159-164.
220. Boston, P. F., Bennett, A., Horrobin, D. F., Bennett, C. N., Ethyl-EPA in Alzheimer's disease - a pilot study. Prostagland. Leukot. Essent. Fatty Acids 2004, 71, 341-346.
221. Dangour, A. D., Andreeva, V. A., Sydenham, E., Uauy, R., Omega3 fatty acids and cognitive health in older people. Brit. J. Nutr. 2012, 107 (Suppl 2), S152-S158.
222. Simopolous, A. P., Leaf, A., Salem, N., Essentiality and recommended dietary intakes for omega-6 and omega-3 fatty acids. Ann. Nutr. Metab. 1999, 43, 127-130.
223. International Society for the Study of Fatty Acids and Lipids, Recommendations for the intake of polyunsaturated fatty acids in healthy adults (ISSFAL Policy Statement 3). http://www.issfal.org/news-links/resources/publications/PUFAIntakeReccomdFinalReport.pdf, 2004.
224. French Agency for Food, Environmental and Occupational Health Safety, The omega-3 fatty acids and thecardiovascular system: Nutritional benefits and claims. http://www.afssa.fr/?Documents?NUT-Ra-omega3EN.pdf, 2003.
225. National Health and Medical Research Council, Nutrient reference values for Australia and New Zealand including recommended dietary intakes. http://www.nhmrc.gov.au/publications/synopses/n35syn.htm, 2006.
226. Food and Agricultural Organisation of the United Nations, Fat and Fatty Acids in Human Nutrition: Report of an Expert Consultation. Food and Agricultural Organisation of the United Nations, Rome (Italy), 2010.
227. European Food Safety Authority, Scientific opinion on dietarty reference values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids and cholesterol. EFSA J. 2010, 8, 1461.
228. Koletzko, B., Cetin, I., Brenna, J. T., Dietary fat intakes for pregnant and lactating women. Brit. J. Nutr. 2007, 98, 873-8877.
229. van der Werf, F., Bax, J., Betriu, A., Blomstrom-Lundqvist, C., et al., Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur. Heart. J. 2008, 29, 2909-2945.
230. JBS2, Joint British societies guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005, 91 (Suppl 5), v1-v52.